Neuren Pharmaceuticals has been growing earnings at an average annual rate of 52.9%, while the Pharmaceuticals industry saw earnings growing at 10.7% annually. Revenues have been growing at an average rate of 50.5% per year. Neuren Pharmaceuticals's return on equity is 9%, and it has net margins of 47.1%.
Key information
52.95%
Earnings growth rate
53.05%
EPS growth rate
Pharmaceuticals Industry Growth
5.95%
Revenue growth rate
50.53%
Return on equity
8.99%
Net Margin
47.08%
Last Earnings Update
31 Dec 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Neuren Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:NURP.F Revenue, expenses and earnings (AUD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
65
30
6
0
30 Sep 25
142
90
6
0
30 Jun 25
219
149
5
0
31 Mar 25
218
146
5
0
31 Dec 24
217
142
5
0
30 Sep 24
206
130
5
0
30 Jun 24
195
117
5
0
31 Mar 24
214
137
6
0
31 Dec 23
232
157
6
0
30 Sep 23
155
106
5
0
30 Jun 23
78
55
4
0
31 Mar 23
47
28
4
0
31 Dec 22
15
0
3
0
30 Sep 22
9
-3
3
0
30 Jun 22
3
-7
3
0
31 Mar 22
3
-7
3
0
31 Dec 21
3
-8
2
0
30 Sep 21
2
-10
2
0
30 Jun 21
1
-12
2
0
31 Mar 21
1
-11
2
0
31 Dec 20
1
-9
2
0
30 Sep 20
1
-8
2
0
30 Jun 20
0
-8
2
0
31 Mar 20
0
-9
2
0
31 Dec 19
0
-11
2
0
30 Sep 19
7
-6
2
0
30 Jun 19
14
-1
2
0
31 Mar 19
14
1
2
0
31 Dec 18
14
3
2
0
30 Sep 18
7
3
2
0
30 Jun 18
1
3
1
0
31 Mar 18
1
3
2
0
31 Dec 17
1
3
2
0
30 Sep 17
2
-2
2
0
30 Jun 17
3
-8
2
0
31 Mar 17
3
-10
2
0
31 Dec 16
3
-12
2
0
30 Sep 16
2
-14
2
0
30 Jun 16
0
-15
3
0
31 Mar 16
1
-14
3
0
31 Dec 15
2
-13
3
0
30 Sep 15
2
-11
3
0
Quality Earnings: NURP.F has high quality earnings.
Growing Profit Margin: NURP.F's current net profit margins (47.1%) are lower than last year (65.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NURP.F has become profitable over the past 5 years, growing earnings by 52.9% per year.
Accelerating Growth: NURP.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NURP.F had negative earnings growth (-78.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-4.8%).
Return on Equity
High ROE: NURP.F's Return on Equity (9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/09 20:30
End of Day Share Price
2026/06/30 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuren Pharmaceuticals Limited is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.